SR 202 (CAT: I010498) emerges as a selective peroxisome proliferator-activated receptor gamma (PPARγ) antagonist. PPARγ is a nuclear receptor involved in the regulation of glucose and lipid metabolism, making it a target for the treatment of diabetes and obesity. By acting as an antagonist, SR 202 modulates PPARγ activity, which has implications in managing diabetes and obesity. Its role as an antidiabetic and antiobesity agent highlights SR 202’s potential significance in pharmaceutical research, offering insights into the development of therapeutic interventions that address metabolic disorders and promote better management of these conditions.
| Catalog Number | I010498 |
| CAS Number | 76541-72-5 |
| Synonyms | Alternative Name: Mifobate |
| Molecular Formula | C11H17ClO7P2 |
| Purity | 95% |
| Target | PPAR |
| Solubility | Soluble to 100 mM in water |
| Storage | Desiccate at RT |
| IUPAC Name | [(4-chlorophenyl)-dimethoxyphosphorylmethyl] dimethyl phosphate |
| InChI | InChI=1S/C11H17ClO7P2/c1-15-20(13,16-2)11(19-21(14,17-3)18-4)9-5-7-10(12)8-6-9/h5-8,11H,1-4H3 |
| InChIKey | VQHUQHAPWMNBLP-UHFFFAOYSA-N |
| SMILES | COP(=O)(C(C1=CC=C(C=C1)Cl)OP(=O)(OC)OC)OC |
